Literature DB >> 5545123

Complement-derived leukotactic factors in inflammatory synovial fluids of humans.

P A Ward, N J Zvaifler.   

Abstract

A large per cent of rheumatoid synovial fluids contain chemotactic activity for rabbit granulocytes (neutrophilic). The chemotactic activity is, in large part, related to the fifth (C5) and sixth (C6) components of human complement; a combination of physical-chemical techniques indicates the activity to be attributable to C567 and C5a, a cleavage product of C5. Many rheumatoid synovial fluids contain a C5-cleaving enzyme which, on the basis of substrate specificity and susceptibility to inhibitors, is very similar to an enzyme extractable from lysosomal granules of human and rabbit granulocytes. Inflammatory nonrheumatoid synovial fluids contain chemotactic activity that is related to cleavage products (C3a) of the third component of human complement (C3). Also found in these fluids is a C3-cleaving enzyme capable of producing C3a. Of the other synovial fluids examined, lupus fluids were remarkable by their total lack of chemotactic activity. These findings record for the first time the presence of complement-derived chemotactic factors in pathological human fluids.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5545123      PMCID: PMC291969          DOI: 10.1172/JCI106531

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Presence of aggregated gamma-G-globulin in certain rheumatoid synovial effusions.

Authors:  K Hannestad
Journal:  Clin Exp Immunol       Date:  1967-07       Impact factor: 4.330

2.  Further studies on the chemotactic factor of complement and its formation in vivo.

Authors:  P A Ward; C G Cochrane; H J Muller-Eberhard
Journal:  Immunology       Date:  1966-08       Impact factor: 7.397

3.  Reactions of aggregated mercaptoethanol treated gamma globulin with rheumatoid factor--precipitin and complement fixation studies.

Authors:  N J Zvaifler; P Schur
Journal:  Arthritis Rheum       Date:  1968-08

4.  The removal of aggregated and nonaggregated autologous gamma globulin from rheumatoid joints.

Authors:  A J Sliwinski; N J Zvaifler
Journal:  Arthritis Rheum       Date:  1969-10

5.  Breakdown products of C 3 in human synovial fluids.

Authors:  N J Zvaifler
Journal:  J Clin Invest       Date:  1969-08       Impact factor: 14.808

6.  The enzymatic nature of C'1r. Conversion of C'1s to C'1 esterase and digestion of amino acid esters by C'1r.

Authors:  G B Naff; O S Ratnoff
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

7.  C3 leukotactic factors produced by a tissue protease.

Authors:  J H Hill; P A Ward
Journal:  J Exp Med       Date:  1969-09-01       Impact factor: 14.307

8.  A plasmin-split fragment of C'3 as a new chemotactic factor.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

9.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  50 in total

1.  Effect of hog anaphylatoxin (C 5a) on vascular permeability and leukocyte emigration in vivo.

Authors:  B Damerau; W Vogt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

2.  A unique complement derived chemotactic factor for tumor cells.

Authors:  A G Romualdez; P A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

3.  Studies of the action of some anti-inflammatory drugs on complement mediated immune haemolysis.

Authors:  K Whaley; D J Sloane
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

4.  Modulation of the inflammatory response by products released from human polymorphonuclear leukocytes during phagocytosis : Generation and inactivation of the chemotactic factor C5a.

Authors:  D G Wright; J I Gallin
Journal:  Inflammation       Date:  1975-03       Impact factor: 4.092

5.  Complement depletion aggravates Staphylococcus aureus septicaemia and septic arthritis.

Authors:  E Sakiniene; T Bremell; A Tarkowski
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  Inhibition of neutrophil migration by sera from patients with rheumatoid arthritis.

Authors:  A S Kemp; P Roberts-Thomson; S H Neoh; S Brown
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

7.  Acute immunologic arthritis in rabbits.

Authors:  C V DeShazo; P M Henson; C G Cochrane
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

8.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

Review 9.  Rheumatoid arthritis: a view of the current genetic landscape.

Authors:  M J H Coenen; P K Gregersen
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

10.  Plasma and synovial fluid levels of granulocytal elastase-alpha-1-protease inhibitor complex in patients with rheumatoid arthritis.

Authors:  K Kuramitsu; A Yoshida
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.